ArticleInfection and drug resistance2020
Fecal Carriage and Molecular Epidemiology of Carbapenem-Resistant
Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Prevalence and incidence of carbapenem-resistant K. pneumoniae colonization: systematic review and meta-analysis.Systematic reviews · 2022Pooled it
- A nomogram for assessing secondary infection risk in hospitalized patients with intestinal CRE colonization: a prospective cohort study.Annals of clinical microbiology and antimicrobials · 2026Article
- Gut Microbiome and Intestinal Colonization with Multidrug-Resistant Strains of Enterobacterales: An Interplay Between Microbial Communities.Antibiotics (Basel, Switzerland) · 2025Review
- Prevalence of β-lactam antibiotic resistance of Escherichia coli isolated from a neonatal intensive care unit.BMC pediatrics · 2025Article
- Fecal carriage and molecular characterization of carbapenem-resistantFrontiers in microbiology · 2025Article
- Active screening and molecular epidemiological characteristics of fecal colonization by carbapenem-resistantFrontiers in public health · 2025Article
- Extended-Spectrum Beta-Lactamase- and Plasmidic AmpC-ProducingMicroorganisms · 2024Article
- Asymptomatic gastrointestinal carriage of multidrug-resistant carbapenemase-producing Enterobacteriaceae among children under five years in a Kenyan hospital.IJID regions · 2023Article
- Fecal Carriage of Carbapenem ResistantInfection and drug resistance · 2023Article
- Dissemination of High-Risk ClonesMicroorganisms · 2022Article
- Community Fecal Carriage and Molecular Epidemiology of Extended-Spectrum β-Lactamase- and Carbapenemase-ProducingInfection and drug resistance · 2022Article
- A Recombinase Aided Amplification Assay for Rapid Detection of theFrontiers in cellular and infection microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine the epidemiology characteristics of intestinal colonization of carbapenem-resistant
methodsA retrospective study was conducted from April to December 2019. Medical records were reviewed to extract the clinical information. Antimicrobial susceptibility was performed by broth microdilution method. Drug resistance determinants and plasmid types were analyzed using polymerase chain reaction (PCR) assays. Multilocus sequence typing (MLST) and Enterobacterial repetitive intergenic consensus sequences PCR (ERIC-PCR) were employed to determine the genetic relationships between strains.
resultsA total of 90 CRE strains were isolated, with a fecal carriage rate of 8.6% (90/1052), and mainly distributed in
conclusionThis study revealed a major intestinal colonization of ST4 NDM-5
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.